Cardiff Oncology...announced that the Company will host a key opinion leader (KOL) webinar to discuss data from an investigator-initiated trial on onvansertib's single-agent clinical activity in chronic myelomonocytic leukemia (CMML).

onvansertib (PCM-075) - Cardiff Oncology

Apr 27, 2026